Chinese the pathogenesis of Alzheimer's disease has "heterogeneity"

　　Medicine Network January 20 , a 17-year-old family Alzheimer's disease study involving 404 families in China was recently published in the international journal Alzheimer's disease and dementia The results suggest that Chinese differ from other races in the genetic mechanisms of family Alzheimer's disease, which has a large number of unknown genes to be discovered by researchers the study was carried out by a team of Professors Jia Jianping of Xuanwu Alzheimer's disease is a common disease in the elderly, but family Alzheimer's disease is relatively rare, accounting for no more than 5% of Alzheimer's patients In 2005, Jia Jianping's team reported the first case of family Alzheimer's disease in China, opening the way for genetic research into Alzheimer's disease Team member, Xuanwu Hospital Neuro
High Center for High-Invasive Center physician Jia Longfei introduced, the international study of family Alzheimer's disease began in the 1970s, for many years has been believed that there are three main genes mutations will lead to family Alzheimer's disease, these three genes are oxytocin 1, oxytocin 2 and amyloid precursor protein The study found 50 mutation sites in the three genes, 11 of which were first reported internationally, suggesting a "heterogeneity" in the pathogenesis between Chinese and other races In addition, 83.17 percent of the 404 families did not carry mutations with three known genes, suggesting that there are still a large number of unknown mutations to be discovered by researchers Professor Jia Jianping's team began in 2002 to establish the nation's largest family Alzheimer's disease registry network, collecting family Alzheimer's cases nationwide, and collecting 404 families, including more than 3,700 family members, by September 2019 The network is also the world's largest family Alzheimer's registration network "In the future, it is hoped that the body cells of adults will be edited to reverse genetic defects and find new breakthroughs in the eventual cure of family Alzheimer's disease "